Search results
Results from the WOW.Com Content Network
Metformin is the British Approved Name (BAN), the United States Adopted Name (USAN), and the International Nonproprietary Name (INN). It is sold under several brand names. Common brand names include Glucophage, Riomet, Fortamet, and Glumetza in the US. [170]
SGLT2 inhibitor. SGLT2 inhibitors (also called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney), unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. The foremost metabolic effect of this is to inhibit reabsorption of ...
The fixed-dose combination product, dapagliflozin/metformin extended-release, is called Xigduo XR. [ 55 ] [ 56 ] [ 57 ] In July 2016, the fixed-dose combination of saxagliptin and dapagliflozin was approved for medical use in the European Union and is sold under the brand name Qtern. [ 58 ]
[4] [5] It is a combination of dapagliflozin and metformin [4] and is taken by mouth. [4] Dapagliflozin/metformin was approved for use in the European Union in January 2014, [ 3 ] in the United States in February 2014, [ 5 ] [ 6 ] and in Australia in July 2014.
In December 2020, the US Food and Drug Administration (FDA) approved labeling changes stating that Januvia (sitagliptin), Janumet (sitagliptin and metformin hydrochloride), and Janumet XR (sitagliptin and metformin hydrochloride extended-release) are not proven to improve glycemic (blood sugar) control in children aged 10 to 17 with type 2 ...
Empagliflozin/metformin was approved for use in the European Union in May 2015. [5] Empagliflozin/metformin was approved for use in the United States in August 2015. [6] [11] The extended release version was approved for use in the United States in December 2016. [12] [13] Empagliflozin/metformin was approved for use in Australia in May 2020. [2]
To reduce the risk of developing ketoacidosis (a serious condition where the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medications, recommending they be temporarily stopped before scheduled surgery.
In December 2020, the U.S. Food and Drug Administration (FDA) approved labeling changes stating that Januvia (sitagliptin), Janumet (sitagliptin and metformin hydrochloride), and Janumet XR (sitagliptin and metformin hydrochloride extended-release) are not proven to improve glycemic (blood sugar) control in children aged 10 to 17 with type 2 ...